

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1 - 10. canceled

11. (newly added): A pharmaceutical composition comprising a corticosteroid, a propellant, a cosolvent, and an antioxidant, wherein said corticosteroid is selected from the group consisting of budesonide, flunisolide, triamcinolone acetonide, fluticasone propionate, ciclesonide, mometasone furoate, and rofleponide.

12. (newly added): The pharmaceutical composition of claim 11, wherein said antioxidant is ascorbyl palmitate.

13. (newly added): The pharmaceutical composition of claim 11, wherein said antioxidant is a tocopherol ester.

14. (newly added): The pharmaceutical composition of claim 11, wherein said antioxidant is selected from the group consisting of ascorbic acid, ascorbyl palmitate, butylated hydroxytoluene, butylated hydroxyanisole, and tocopherol esters.

15. (newly added): The pharmaceutical composition of claim 11, wherein the corticosteroid is budesonide.

16. (newly added): The pharmaceutical composition of claim 11, wherein the propellant is 1,1,1,2- tetrafluoroethane, 1,1,1,2,3,3,3- heptafluoropropane, or a mixture thereof.

17. (newly added): The pharmaceutical composition of claim 11, wherein said cosolvent is an alcohol.

18. (newly added): The pharmaceutical composition of claim 17, wherein said alcohol is ethanol.

19. (newly added): A pressurized metered dose inhaler comprising a container equipped with a metering valve and containing a pressurized aerosol formulation comprising a corticosteroid, a propellant, a cosolvent, and an antioxidant, wherein said corticosteroid is selected from the group consisting of budesonide, flunisolide, triamcinolone acetonide, fluticasone propionate, ciclesonide, mometasone furoate, and rofleponide.

20. (newly added): The pressurized metered dose inhaler according to claim 19, wherein the corticosteroid is budesonide.

21. (newly added): The pressurized metered dose inhaler according to claim 19, wherein said propellant is 1,1,1,2- tetrafluoroethane, 1,1,1,2,3,3,3- heptafluoropropane, or a mixture thereof.

22. (newly added): The pressurized metered dose inhaler according to claim 19,
wherein said cosolvent is an alcohol.

23. (newly added): The pressurized metered dose inhaler according to claim 22,
wherein said alcohol is ethanol.

24. (newly added): The pressurized metered dose inhaler according to claim 19,
wherein said antioxidant is ascorbyl palmitate.

25. (newly added): The pressurized metered dose inhaler according to claim 19,
wherein said antioxidant is a tocopherol ester.

26. (newly added): A method for the treatment of a bronchial disorder comprising
administering a pharmaceutical formulation comprising a corticosteroid, a propellant, a
cosolvent, and an antioxidant, wherein said corticosteroid is selected from the group
consisting of budesonide, flunisolide, triamcinolone acetonide, fluticasone propionate,
ciclesonide, mometasone furoate, and rofleponide.

27. (newly added): The method according to claim 26, wherein said corticosteroid is
budesonide.

28. (newly added): The method according to claim 26, wherein said propellant is
1,1,1,2- tetrafluoroethane, 1,1,1,2,3,3,3- heptafluoropropane or a mixture thereof.

29. (newly added): The method according to claim 26, wherein said cosolvent is an alcohol.

30. (newly added): The method according to claim 29, wherein said alcohol is ethanol.

31. (newly added): The method according to claim 26, wherein said antioxidant is ascorbyl palmitate.

32. (newly added): The method according to claim 26, wherein said antioxidant is a tocopherol ester.

SUPPORT FOR THE AMENDMENTS

Applicants have canceled Claims 1-23 and added new Claims 24-45.

Claim 11 is supported by page 7, line 8, to page 9, line 1; and original Claims 1 and 3;

Claim 12 is supported by page 7, line 13, to page 8, line 6;

Claim 13 is supported by page 7, line 13, to page 8, line 6;

Claim 14 is supported by page 7, line 13, to page 8, line 6;

Claim 15 is supported by page 10, lines 6-9;

Claim 16 is supported by page 2, lines 7-12; and original Claim 6;

Claim 17 is supported by page 7, lines 11-12;

Claim 18 is supported by page 7, lines 11-12;

Claim 19 is supported by page 7, line 8, to page 9, line 1; and original Claims 1 and 3;

Claim 20 is supported by page 10, lines 6-9;

Claim 21 is supported by page 2, lines 7-12; and original Claim 6;

Claim 22 is supported by page 7, lines 11-12;

Claim 23 is supported by page 7, lines 11-12;

Claim 24 is supported by page 7, line 13, to page 8, line 6;

Claim 25 is supported by page 7, line 13, to page 8, line 6;

Claim 26 is supported by page 7, line 8, to page 9, line 1; and original Claims 1 and 3;

Claim 27 is supported by page 10, lines 6-9;

Claim 28 is supported by page 2, lines 7-12; and original Claim 6;

Claim 29 is supported by page 7, lines 11-12;

Claim 30 is supported by page 7, lines 11-12;

Claim 31 is supported by page 7, line 13, to page 8, line 6; and